-
,for, Item ID-
- #952614
- Providers like you icon 1,463
- Merck #00006412102
Gardasil® 9 Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free 20 mcg - 60 mcg / 0.5 mL Injection 0.5 mL
GARDASIL 9 HPV VACC, SYR 0.5ML(10/BX)
Features
- GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
- Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
- More …
Product Details Email
Product Specifications
McKesson # | 952614 |
---|---|
Manufacturer # | 00006412102 |
Brand | Gardasil® 9 |
Manufacturer | Merck |
Country of Origin | Austria |
Application | Human Papillomavirus Vaccine (HPV) |
Container Type | Prefilled Syringe |
Dosage Form | Injection |
Generic Drug Code | 37568 |
Generic Drug Name | Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free |
NDC Number | 00006412102 |
Product Dating | McKesson Acceptable Dating: we will ship >= 180 days |
Storage Requirements | Requires Refrigeration |
Strength | 20 mcg - 60 mcg / 0.5 mL |
Type | Intramuscular |
UNSPSC Code | 51201649 |
User | Indicated for People 9 to 45 Years of Age |
Volume | 0.5 mL |
Features
- GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
- Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
- Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58
Frequently Viewed Together
-
,for, Item ID-
- #765875
- McKesson Brand #14-6976C
-
,for, Item ID-
- #881399
- McKesson Brand #2262
-
,for, Item ID-
- #570560
- Nephron Pharmaceutical #00487950125
-
,for, Item ID-
- #772678
- Glaxo Smith Kline #58160084252
-
,for, Item ID-
- #462548
- American Regent #00517003125
-
,for, Item ID-
- #1199151
- Pfizer (RSV Vaccines) #00005200010
-
,for, Item ID-
- #1110687
- Sanofi Pasteur #49281040020
-
,for, Item ID-
- #1177399
- Quidel #20377
-
,for, Item ID-
- #1141855
- Abbott Rapid Dx North America LLC #1116975
-
,for, Item ID-
- #769341
- Glaxo Smith Kline #58160082152
-
,for, Item ID-
- #1238106
- Merck #00006468100
-
,for, Item ID-
- #848309
- Kedrion Biopharma #00562780505
-
,for, Item ID-
- #276842
- Merck #00006482700
-
,for, Item ID-
- #327341
- Sanofi Pasteur #49281086010
-
,for, Item ID-
- #1081079
- Glaxo Smith Kline #58160082311